A Story of Heavy Ion Therapy for Gynecological Cancer Patients
A Story of Heavy Ion Therapy for Gynecological Cancer Patients
——Precision Heavy Ion Treatment for Locally Advanced Cervical Squamous Cell Carcinoma
Case Study:
"Ms. Xu, 57, was unfortunate—she was diagnosed with cervical cancer, and at an advanced stage, just after retiring this year. This meant she could not undergo radical surgery and could only rely on chemotherapy and radiotherapy to fight the tumor. Yet, she was also fortunate. Under the meticulous care of the gynecological oncology heavy ion therapy team at Wuwei Medical Science Research Institute Cancer Hospital and the guidance of an MDT (multidisciplinary team), she remained free of recurrence or metastasis after two years of follow-up.
The Beginning of Her Fight: Standard Treatment Yields Good Results
Five years ago, Ms. Xu sought medical attention at major hospitals in Xinjiang due to "irregular vaginal bleeding." A cervical biopsy revealed "moderately differentiated squamous cell carcinoma of the cervix." Ultrasound showed a solid mass (60×43 mm) in the cervix and vagina with irregular morphology and infiltration into surrounding tissues, extending upward to the lower uterine segment and downward into the vagina. Pelvic MRI indicated a mass-like abnormal signal in the cervical region, measuring approximately 50×49 mm in cross-section and 50 mm in length, protruding into the uterine cavity and vagina. Pathology confirmed non-keratinizing, poorly differentiated squamous cell carcinoma.
Stage III cervical cancer is considered advanced, and for Ms. Xu, this was devastating. With only radiotherapy and chemotherapy as treatment options, she nearly lost hope. However, during a flight to Beijing for a follow-up examination, Ms. Xu and her family saw an advertisement about heavy ion therapy for cancer. They immediately called Wuwei Heavy Ion Center for consultation. Holding onto their last hope, they traveled to Wuwei.
Ms. Xu visited the outpatient clinic of Dr. Dang Youquan, Director of the Gynecological Oncology Heavy Ion Therapy Department at Wuwei Medical Science Research Institute Cancer Hospital. After a thorough evaluation, Dr. Dang concluded that heavy ion therapy could still offer her a chance—reducing tumor burden, improving quality of life, and extending survival.
Prior to this, Ms. Xu had undergone two cycles of neoadjuvant chemotherapy (TP regimen: paclitaxel 300mg + carboplatin 600mg, IV, Q21D) at another hospital, followed by pelvic external beam radiotherapy (IMRT: cervix + pelvic lymph node drainage area: 46Gy; parametrium: 56Gy, 27 fractions) with concurrent TP chemotherapy. After completing external radiotherapy and chemoradiotherapy, she was admitted to Wuwei for heavy ion therapy.
In March 2021, she began carbon ion radiotherapy with a total local dose of 100GyE/26 fractions, alongside one cycle of concurrent TP chemotherapy.
Ms. Xu showed excellent compliance, strictly adhering to blood tests and examinations, ensuring a smooth treatment process. After therapy, her vaginal bleeding completely stopped, and imaging showed partial response (PR)—meaning the aggressive advanced cervical cancer had been controlled.
Three months post-treatment, a gynecological examination found no palpable cervical mass. A follow-up PET-CT scan confirmed no residual or recurrent malignancy. Due to travel constraints, Ms. Xu continued follow-ups locally while maintaining remote consultations with Wuwei.
Now, 24 months later, she remains in complete remission (CR) with no recurrence or metastasis. "This case proves that even with refractory tumors, we must never give up," said Dr. Dang Youquan, deeply moved by her success.
MRI Before Treatment (March 2021)
MRI 5 Months Post-Treatment (August 2021)
Unique Advantages of Heavy Ion Therapy
Heavy ion radiotherapy offers distinct physical and biological benefits:
- Higher energy deposition in tumors compared to conventional radiation.
- Precise energy release, minimizing damage to healthy tissues.
- Independent of cell cycle or oxygen levels for tumor killing.
- Induces DNA double-strand breaks, preventing cancer cell proliferation.
- Enhances immune response, with abscopal and bystander effects.
- Higher relative biological effectiveness (RBE).
- Less pain and fewer complications than photon radiotherapy.
Superior Local Control Rates
According to NCCN guidelines, radiotherapy (with or without chemotherapy) is the standard for cervical cancer beyond stage IA. However, larger tumors (>5 cm) have poorer outcomes:
- Conventional radiotherapy: 47.7–72% 2-year pelvic control for tumors >5 cm.
- Carbon ion therapy: 63–100% 10-year local control for stage II–IVA, regardless of tumor size.
Additionally, cervical adenocarcinomas (radioresistant) show:
- Photon therapy: 36–58% 5-year local control.
- Carbon ion therapy: 55–71% local control, with improved survival.
Heavy ions also overcome hypoxia-induced radiation resistance, making them ideal for bulky or radioresistant tumors.
About Wuwei Heavy Ion Center
As China’s first clinical heavy ion center, Wuwei has treated 794+ patients since March 2020, specializing in complex cases (brain, pancreas, lung, etc.). The center integrates comprehensive cancer care, immunotherapy, TCM, rehabilitation, and holistic wellness, pioneering a full-lifecycle health management system.
Department of Gynecological Oncology Heavy Ion Therapy
Specialties: Heavy ion/photon radiotherapy for breast, cervical, endometrial, ovarian, vaginal, and vulvar cancers.
Team: 13 members, including 2 associate chief physicians.
Consultants: Prof. Liu Zi (Xi’an Jiaotong University), Prof. Li Sha (PLA 940 Hospital), and Taiwan experts Prof. Ren Yimin & Prof. Wu Jiaming.
Advanced Techniques:
- Heavy ion therapy
- Stereotactic radiotherapy (SRS/SABR/SBRT)
- IMRT/IGRT/3D-CRT
- Brachytherapy & hyperthermia
Contact:
- Hotline: 400-609-6666
- Dr. Dang: 138-9358-0468
- Address: Gynecological Oncology Heavy Ion Therapy Dept., Wuwei Medical Science Research Institute Cancer Hospital, Gansu, China